UPDATED: Celgene pays $1B in landmark deal to buy into Juno’s pipeline of CAR-T drugs

John Carroll

is paying about $ 1 billion to move to the front of the hectic race to build new CAR-T cancer therapies. The Big Biotech is shelling out $ 150 million upfront and paying $ 93 a share–a huge premium–to snap up 9.1 million shares of Juno Therapeutics, inking a collaboration to develop and commercialize new oncology therapies.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS